These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 34328195)

  • 1. Galectin‑3 blockade suppresses the growth of cetuximab‑resistant human oral squamous cell carcinoma.
    Yin P; Cui S; Liao X; Yao X
    Mol Med Rep; 2021 Oct; 24(4):. PubMed ID: 34328195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined cetuximab and celecoxib treatment exhibits a synergistic anticancer effect on human oral squamous cell carcinoma in vitro and in vivo.
    Qian M; Qian D; Jing H; Li Y; Ma C; Zhou Y
    Oncol Rep; 2014 Oct; 32(4):1681-8. PubMed ID: 25328959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined cetuximab and genistein treatment shows additive anti-cancer effect on oral squamous cell carcinoma.
    Park SJ; Kim MJ; Kim YK; Kim SM; Park JY; Myoung H
    Cancer Lett; 2010 Jun; 292(1):54-63. PubMed ID: 19959278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resveratrol Targets Urokinase-Type Plasminogen Activator Receptor Expression to Overcome Cetuximab-Resistance in Oral Squamous Cell Carcinoma.
    Uzawa K; Amelio AL; Kasamatsu A; Saito T; Kita A; Fukamachi M; Sawai Y; Toeda Y; Eizuka K; Hayashi F; Kato-Kase I; Sunohara M; Iyoda M; Koike K; Nakashima D; Ogawara K; Endo-Sakamoto Y; Shiiba M; Takiguchi Y; Yamauchi M; Tanzawa H
    Sci Rep; 2019 Aug; 9(1):12179. PubMed ID: 31434965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of BMP signaling overcomes acquired resistance to cetuximab in oral squamous cell carcinomas.
    Yin J; Jung JE; Choi SI; Kim SS; Oh YT; Kim TH; Choi E; Lee SJ; Kim H; Kim EO; Lee YS; Chang HJ; Park JY; Kim Y; Yun T; Heo K; Kim YJ; Kim H; Kim YH; Park JB; Choi SW
    Cancer Lett; 2018 Feb; 414():181-189. PubMed ID: 29154973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective inhibition of PI3K110α as a novel therapeutic strategy for cetuximab‑resistant oral squamous cell carcinoma.
    Tsuchihashi H; Naruse T; Yanamoto S; Okuyama K; Furukawa K; Omori K; Umeda M
    Oncol Rep; 2020 Sep; 44(3):863-872. PubMed ID: 32705230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LncRNA UCA1 promotes proliferation and cisplatin resistance of oral squamous cell carcinoma by sunppressing miR-184 expression.
    Fang Z; Zhao J; Xie W; Sun Q; Wang H; Qiao B
    Cancer Med; 2017 Dec; 6(12):2897-2908. PubMed ID: 29125238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. miR-182-5p Promotes Growth in Oral Squamous Cell Carcinoma by Inhibiting CAMK2N1.
    Li N; Nan CC; Zhong XY; Weng JQ; Fan HD; Sun HP; Tang S; Shi L; Huang SX
    Cell Physiol Biochem; 2018; 49(4):1329-1341. PubMed ID: 30205384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy and potential mechanisms of pyrotinib in targeting EGFR and HER2 in advanced oral squamous cell carcinoma.
    Zhou L; Le K; Chen Q; Wang H
    BMC Oral Health; 2024 Aug; 24(1):898. PubMed ID: 39107736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hsa_circ_0005379 regulates malignant behavior of oral squamous cell carcinoma through the EGFR pathway.
    Su W; Wang Y; Wang F; Sun S; Li M; Shen Y; Yang H
    BMC Cancer; 2019 Apr; 19(1):400. PubMed ID: 31035951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance of oral squamous cell carcinoma cells to cetuximab is associated with EGFR insensitivity and enhanced stem cell-like potency.
    Ohnishi Y; Minamino Y; Kakudo K; Nozaki M
    Oncol Rep; 2014 Aug; 32(2):780-6. PubMed ID: 24926885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Migration of oral squamous cell carcinoma cells are induced by HGF/c-Met signalling via lamellipodia and filopodia formation.
    Yasui H; Ohnishi Y; Nakajima M; Nozaki M
    Oncol Rep; 2017 Jun; 37(6):3674-3680. PubMed ID: 28440510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancement of Histone Deacetylase Inhibitor Sensitivity in Combination with Cyclin-Dependent Kinase Inhibition for the Treatment of Oral Squamous Cell Carcinoma.
    Zhao B; Huang Z; Qin Z; Li Y; Wang T; Wang L; Zhou W; Yu C; Wang X; Yang S; Fan Y; Xiang R
    Cell Physiol Biochem; 2019; 53(1):141-156. PubMed ID: 31237760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urolithin A, induces apoptosis and autophagy crosstalk in Oral Squamous Cell Carcinoma via mTOR /AKT/ERK1/2 pathway.
    Remadevi V; Jaikumar VS; Vini R; Krishnendhu B; Azeez JM; Sundaram S; Sreeja S
    Phytomedicine; 2024 Jul; 130():155721. PubMed ID: 38788395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of NLRP3 inflammasome in 5-fluorouracil resistance of oral squamous cell carcinoma.
    Feng X; Luo Q; Zhang H; Wang H; Chen W; Meng G; Chen F
    J Exp Clin Cancer Res; 2017 Jun; 36(1):81. PubMed ID: 28637493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paclitaxel in combination with cetuximab exerts antitumor effect by suppressing NF-κB activity in human oral squamous cell carcinoma cell lines.
    Harada K; Ferdous T; Kobayashi H; Ueyama Y
    Int J Oncol; 2014 Dec; 45(6):2439-45. PubMed ID: 25230791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in vivo anti-tumor effect of metformin as a novel therapeutic agent in human oral squamous cell carcinoma.
    Luo Q; Hu D; Hu S; Yan M; Sun Z; Chen F
    BMC Cancer; 2012 Nov; 12():517. PubMed ID: 23151022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EGFR-mediated signaling pathway influences the sensitivity of oral squamous cell carcinoma to JQ1.
    Liu X; Li Q; Huang P; Tong D; Wu H; Zhang F
    J Cell Biochem; 2018 Oct; 119(10):8368-8377. PubMed ID: 30687956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced antitumor effect of cisplatin in human oral squamous cell carcinoma cells by tumor suppressor GRIM‑19.
    Li M; Li Z; Li J; Jin L; Jin C; Han C; Ji X; Sun F
    Mol Med Rep; 2015 Dec; 12(6):8185-92. PubMed ID: 26458285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cetuximab-resistant oral squamous cell carcinoma cells become sensitive in anchorage-independent culture conditions through the activation of the EGFR/AKT pathway.
    Ohnishi Y; Yasui H; Kakudo K; Nozaki M
    Int J Oncol; 2015 Dec; 47(6):2165-72. PubMed ID: 26497980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.